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Abstract
Breast cancer is a common disease that affects both women and men all over the world.
Triple negative breast cancer is an aggressive subtype of breast cancer with poor survival
statistics and few available treatment options. Uncontrolled cell proliferation and the ability to
avoid programmed cell death, apoptosis, are two shared hallmarks of cancers. Previous research
has shown a group of heterocyclic molecules called triaminopyrimidines may be effective
antiproliferative agents. Previous research has also shown that some gold(I) complexes may be
promising anticancer agents. In this study, a few chemicals from both of these types of molecules
were examined for their effect in the triple negative breast cancer cell line, MDA-MB-231. To
our knowledge, none of the chemicals examined in this study were previously tested for their
effects on cancer. Four triaminopyrimidine derivative compounds and four gold(I) chloride
compounds were tested in this study for their ability to inhibit cell proliferation as well as their
ability to induce apoptosis. The method used in this study to assess cell proliferation include the
3-[4,5-dimethyl-2-thiazolyl]-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. Staining with
acridine orange and propidium iodide was performed in order to assess the induction of cellular
apoptosis. Statistical analysis was performed by Student’s t-test to determine whether a
compound caused significant inhibition of cellular proliferation or induction of cellular
apoptosis. Probit analysis was used to calculate IC50 values for each compound. Results show
that one or more of the triaminopyrimidine compounds as well as gold(I) chloride compounds
significantly inhibit MDA-MB-231 cellular proliferation. These select compounds also exhibit
the ability to induce apoptosis in the MDA-MB-231 cell line. In conclusion, future studies will
need to be carried out to determine possible mechanisms of action.
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Introduction
Cancer
Cancer is a collection of diseases that share a group of defining characteristics. These
defining characteristics are commonly referred to as the “Hallmarks of Cancer”. Two of these
hallmarks are: cancer cells have uncontrolled cell proliferation and evade programmed cell death
or apoptosis. Apoptosis is genetically regulated cell death (Taraphdar 2001). This form of
programmed cell death plays a role in many biological processes and is involved in the growth
and health of cells. Apoptosis plays an important role in many diseases including cancer
(Taraphdar, 2001). In cancer, there can be decreased cell death and inhibition or evasion of
apoptosis. Apoptosis is an active process that begins with the flipping of the phosphatidylserine
of the plasma membrane from the inside of the cell to the outside of the cell, making the cell
recognizable by phagocytes (Taraphdar, 2001).
Cancer cells are also able to activate specific gene pathways for limitless replication
potential. In addition, cancer cells develop angiogenesis, or the ability to gain their own blood
supply and blood vessels. Cancer cells are able to move to and proliferate in different parts of the
body. This last characteristic is referred to as tissue invasion and metastasis meaning cancer cells
can spread to the neighboring tissues or to the distant sites (Hanahan, 2000). Further, compared
to normal cells, cancer cells are large and have different shaped nuclei. Cancer cells can have
disorganized arrangements and display a loss of normal features (Hanahan, 2000).

Breast Cancer
Breast cancer is the most common type of cancer diagnosed in American women, with
the exception of skin cancers (American Cancer Society, 2020). In 2019, it was estimated that
268,600 new cases of breast cancer would be diagnosed in women and 2,670 new cases
diagnosed in men (American Cancer Society, 2020). Approximately, 1 in 8 women will be
diagnosed with invasive breast cancer in their lifetime and 1 in 39 women will die from breast
cancer (American Cancer Society, 2020). As listed by the American Cancer Society, there are six
different types of breast cancer: Ductal Carcinoma in Situ, Invasive Breast Cancer, Triplenegative Breast Cancer, Inflammatory Breast Cancer, Angiosarcoma of the Breast, and Paget
Disease of the Breast (American Cancer Society, 2020).
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Triple Negative Breast Cancer
Triple negative breast cancer is a form of breast cancer where the cells lack receptors for
estrogen (ER), receptors for progesterone (PGR), and human epidermal growth factor receptor 2
(HER2) (Dent, 2007). Triple negative breast cancer is the most aggressive subtype of breast
cancer, currently accounts for 10-20% of all breast cancers (Breastcancer.org, 2020), and has a
poor disease-free survival. There is no effective specific targeted therapy currently available for
triple negative breast cancer hence, it is important to continue to explore therapeutic agents
against triple negative breast cancer. There is a clustering of triple negative breast cancer cases in
premenopausal women and in women of African descent (Wahba, 2015). Breast cancers,
including triple negative breast cancer, diagnosed in elderly women over 65 years are typically
initiated in the postmenopausal period after 60 years of age. These patients are generally non
hormone replacement therapy users and exhibit deepening estrogen deficiency and insulin
resistance, as well as a high prevalence of type 2 diabetes and obesity (Suba, 2014).
Patients diagnosed with breast cancer that is localized, meaning there is no sign that the
cancer has spread outside of the breast, have a five-year survival rate of 91%. Patients diagnosed
with breast cancer that is regional, meaning the cancer has spread outside the breast to nearby
structures including the lymph nodes, have a five-year survival rate of 65%. Patients diagnosed
with breast cancer that is distant, meaning the cancer has spread to distant parts of the body such
as the lungs or bones, have a five-year survival rate of 11% (American Cancer Society, 2020).
Patients with triple negative breast cancer do not benefit from hormonal or trastuzumabbased therapy because of the loss of target receptors such as ER, PGR, and HER-2. Therefore,
surgery and standard chemotherapy targeting DNA synthesis and cell division either individually
or in combination, are the current forms of treatment for triple negative breast cancer (Wahba,
2015). Therefore, it is important to research new and innovative treatments for this cohort of
patients who often display an aggressive form of the disease and resistance to existing
chemotherapies.
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Objective:
The objective of this study was to test twelve unique small molecule compounds
(triaminopyrimidines and gold(I) complexes) as possible new treatment options for triple
negative breast cancer by examining their effect on cell proliferation and apoptosis in MDA-MB231 breast cancer cells.
Heterocyclic Compounds – Triaminopyrimidine analogs
Heterocyclic compounds (e.g., pyridine and pyrimidine rings) are organic molecules with
a ring structure that contain at least two different elements such as nitrogen and oxygen.
Heterocyclic molecules are of particular interest in the field of cancer research because early
studies have shown that they may exhibit anti-cancer properties in colon, lung and breast cancer
cell lines (Shaw, 2012) (Hammam, 2003).
A study from the Indian Journal of Chemistry explored the effect of tricyclic heterocyclic
compounds that include pyridine and pyrimidine rings on the inhibition of cell growth on three
different cell lines: Lung, Breast, and Central nervous system (CNS) cancer cells. Cell lines were
first evaluated using one dose treatment with one of 14 synthesized compounds. The compounds
were formed by synthesizing and condensing the arylmethylene of benzopyrane or
benzothiopyrane with different solvents (Hammam, 2003). The compounds that reduced cell
growth to 32% or less were chosen for a 5-log dose range treatment. It was concluded that of the
heterocyclic compounds tested, 5c (2-acetyl-3-aryl-2,3,3a,-4-tetrahydro-(4H)-[1]benzopyrano[4,3-c]pyrazoles), 9d (2-amino-4-aryl-3,4-dihydro-(5H)-[1]benzopyrano[4,3-d]pyrimidine), and 19d (3’-aryl-(3’H)-(2H)-spiroxariane[2’,3]benzopyran-4-one) had the highest
levels of cell growth inhibition in specific Lung, Breast, and CNS cell lines (Hamman, 2003).

Triaminopyrimidines
Triaminopyrimidines are a class of small heterocyclic compounds that are strong
inhibitors of inflammatory caspases (Kent, 2016). Triaminopyrimidines (Figure 2) are multi-ring
molecules with a pyrimidine ring in the center surrounded by three amine group rings. Adding a
R-group via nucleophilic substitution forms triaminopyrimidine analogs (Figure 3) (Kent, 2016).
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Figure 1: Pyrimidine
structure
(Sigma-Aldrich)

Figure 2: 2,4,6Triaminopyrimidine
chemical structure
(Sigma-Aldrich)

Figure 3:
Triaminopyrimidine analog
structure (Kent, 2016)

The triaminopyrimidine analogs used in this study were synthesized by the Department of
Chemistry and Biochemistry at DePaul University in the lab of Dr. Caitlin E. Karver (Table 1).
Based on their activity on inflammatory caspases, four compounds were chosen to test for their
ability to inhibit breast cancer cell proliferation. Each compound contains the original
triaminopyrimdine analog structure with a unique R-group (Kent, 2016).
These compounds were as follows: CK-1-29, a 3-methoxy variation; CK-1-37, an alkyl
variation; MB-1-19, a 4-methylpyridine variation; and CK-1-4, a ethylbenzene variation of the 4(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyrimidine structure shown in Figure 2. All four
compounds were tested for their ability to inhibit cell proliferation and cause cell death.

Table 1: Triaminopyrimidine analog compound names and structures
Name

Structure

Name

MB-1-19

CK-1-29

(MW: 218.26)

(MW: 261.32)

CK-1-41

CK-1-37

(MW: 231.3)

(MW: 225.28)
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Structure

Studies examining triaminopyrimidine compounds and their anti-proliferative and cell
death inducing effects are very limited and few and far between. This is the first study to
examine these compounds for their anti-proliferative and apoptotic effects in breast cancer cells.
A study in 2006 tested synthesized pyridine (C5H5N), pyran (C5H6O), and pyrimidine
(C4H4N2) derivatives on 59 human tumor cell lines of the Lung, Colon, Brain, Ovary, Breast,
Prostate, and Kidney, for antitumor activity via MTT Assay (Amr, 2006). It was proposed that
the structure of the derived compounds (each one containing a nitrogen heterocyclic ring) plays a
role in their anticancer abilities (Amr, 2006). Of all compounds tested, those that contained
nitrogen heterocyclic rings had the highest levels of anticancer activity as examined by the MTT
Assay. This suggests that nitrogen heterocyclic rings may be essential for anticancer properties.
In the study carried out by Kent (2016), the triaminopyrimidine derivatives 4methylpyridine and 3-methylpyridine displayed high levels of selectivity and inhibition of
caspase-5. Caspase-5 belongs to a family of cysteine proteases involved in apoptosis,
inflammation, proliferation, and differentiation. Caspase-5 is colocalized with the inflammatory
caspases-1, -4, and -12 and is thought to play a role in innate immunity and inflammation (Bian,
2011). Based on the findings from the study mentioned above, it can be suggested that because
4-methylpyridine and 3-methylpyridine have nitrogen heterocyclic rings as part of their
structures, they may be successful anticancer compounds. These compounds were shown to be
successful at inhibiting the inflammatory caspase-5 and therefore may also be an inhibitor of
caspases involved in cancer (Kent, 2016).
In the study carried out by Kent, 2016, CK-1-41 was found to be the most potent
compound of the twelve compounds tested for inhibition of caspase-1, -4 and -5 and had the
highest potency against caspase-4. Kent, et al (2016), hypothesizes that the successfulness of
compound CK-1-41 may be due to greater structural flexibility from the longer carbon chain in
the R-group.
The compound CK-1-29 used in this thesis has a 3-methoxy substitution. CK-1-29 was
found to inhibit all three inflammatory caspases tested (Kent, 2016). In a recent study, 3methoxy arylhydrazone derivatives of salicylaldehyde benzoylhydrazone were tested for
cytotoxic activity on three different human cell lines: human hepatocellular carcinoma (HEP-G2)
human embryonic kidney cells (HEK-293), and human neuroblastoma cells (SH-SY-5Y)
(Hristova-Avakumova, 2017). After a 72-hour incubation period, in vitro cytotoxicity was tested
11

by MTT-dye reduction assay and apoptosis assay. Results showed that all compounds decreased
cell viability in a concentration dependent manner with the lowest concentration being 0.1 µM
and the highest concentration being 25 µM (Hristova-Avakumova, 2017). Therefore, it is
hypothesized that this compound may have similar cytotoxic effects on human cancer cell lines
as the 3-methoxy arylhydrazones tested in the study mentioned above.
Compound CK-1-37 is an alkyl derivative. CK-1-37 was moderately potent against all
three caspases. Kent, et al (2016), hypothesizes that this potency is related to the hydrophobicity
of the structure as well as van der Waals interactions.
Due to the successfulness of compound CK-1-41 in the above study and in our
experiments as well, four derivatives of CK-1-41 were also examined for their therapeutic
potential in the breast cancer cell line, MDA-MB-231 cells (Table 2). The list of these
compounds is as follows: AE-2-23, AE-1-75, AE-1-63, and AE-1-79. All four compounds were
tested for their ability to inhibit cell proliferation and induce cell death in breast cancer cells.

Table 2: CK-1-41 derivative compound names and structures
Name

Structure

Name

AE-1-63

AE-1-79

(MW:

(MW:

412.63)

374.53)

AE-1-75

AE-2-23

(MW:

(MW:

420.61)

384.57)

Structure

Possible Mechanisms of Action of Triaminopyrimidine Compounds
The triaminopyrimidine analogs were previously found to inhibit inflammasome
formation of caspase 1, 4 and 5 in a noncompetitive and time dependent manner (Kent, 2016).
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The inflammasome is formed when caspases activate a complex of proteins as an inflammatory
response to a harmful stimulus (Terlizzi, 2014). In particular, caspase-1 activates NF-κB.
Previous studies have shown that NF-κB promotes tumor cell proliferation, suppresses apoptosis,
and attracts angiogenesis in human cancers (Xia, 2014). NF-κB has also been shown to induce
epithelial-mesenchymal transition, which facilitates distant metastasis (Xia, 2014).
A previous study has shown a triaminopyrimidine referred to as CINK4 to be a weak
inhibitor of cyclin-dependent kinase 4 (Cdk4) (Toogood, 2002). Cdk4 plays a role in cell
proliferation by acting as a checkpoint during the G1 to S phase of cellular replication (O’Leary,
2016). Increased cell proliferation can lead to overexpression of Cdk4 and the overexpression of
Cdk4 has been associated with tumorigenesis. The triaminopyrimidine CINK4 blocks the G1
phase in the cell cycle and inhibits phosphorylation of retinoblastoma protein, thus causing the
unregulated passage of cells from G1 to S phase (Toogood, 2002).
Another study examined triaminopyrimidine cyclobutenedione derivatives and
discovered that these derivatives can have cell division cycle 25 (CDC25) phosphatase inhibiting
properties (Liberatore, 2010). CDC25 regulates the cell cycle and acts as a checkpoint between
the stages of the cell cycle. It checks for DNA damage to ensure genetic stability (Boutros,
2008).
The overexpression of CDC25 phosphatase is a marker in many human cancers, such as
lymphoma, breast cancer, head and neck cancer, and pancreatic cancer (Liberatore, 2010).
CDC25 plays a role in the regulation of cell cycle progression through the activation of cyclindependent kinases. CDC25 is also involved in chromatin modulation and transcriptional
regulation (Brenner, 2017). Mutated CDC25 can lead to unregulated cell proliferation, one of the
hallmarks of cancer (Tian, 2010).
In summary, triaminopyrimidine compounds could be acting through a mechanism that
inhibits transcription factor NF-κB or phosphatase CDC25 in order to restore regulation of the
cell cycle. Triaminopyrimdine compounds may also play a role in arresting the cell cycle
therefore preventing uncontrolled cellular proliferation.

Gold(I) Chloride Compounds
In addition to triaminopyridine compounds, a set of gold(I) chloride compounds were
also tested for their efficacy against triple negative breast cancer cell proliferation and induction
13

of apoptosis. The use of heavy metal compounds as a treatment for cancer began in the mid
1960’s when a platinum compound called cisplatin was discovered to have anticancer properties.
Cisplatin is commonly used to treat genitourinary cancer, in particular testicular cancer.
However, the administration of cisplatin induces severe side-effects and resistance. Resistance to
cisplatin is attributed to three molecular mechanisms: increased DNA repair, altered cellular
accumulation, and increased drug inactivation (Amable, 2016).
In 1890, gold(I) cyanide salt was the first gold compound discovered to possess
biological properties and was researched for its anti-tubercular properties (Benedek, 2004). In
early medicine the therapeutic benefits of gold(I) compounds were limited to inflammatory
diseases, such as rheumatoid arthritis (Brenners-Price, 2011). More recently, gold compounds
have been looked at as possible non-toxic and effective anti-cancer treatments. Auranofin (a
gold(I) compound approved by the FDA in 1985) is commonly used as a treatment for
rheumatoid arthritis due to its immunosuppressive and anti-inflammatory properties. Previous
research has determined that gold(III) dithiocarbamato derivatives are promising anticancer
agents because they are highly stable and have a low toxicity toward healthy tissues (Ronconi,
2010).
A previous study tested the in vitro cytotoxicity of gold(III) compounds on the triple
negative breast cancer cell line MDA-MB-231 and found that gold(III) complexes inhibited
tumor cell growth in a dose-dependent manner with IC50 values in the low micro molar range
(Nardon, 2014). Furthermore, these gold(III) compounds were tested as proteasome inhibitors
(Nardon, 2014). Gold complexes are thought to be involved in many different pathways resulting
in the modification of the cell cycle and other cell processes eventually leading to apoptosis.
Because of their involvement in many different cellular processes, it is possible that not all gold
compounds operate via the same mechanism of action. Gold(I) compounds have a tendency to
form stable complexes because of their soft metal center, compared to the hard center of gold(III)
compounds (Tiekink, 2002). It has been suggested that gold(III) compounds are more susceptible
to reduction in biological environments (Zou, 2016). Gold in the oxidative state of (+III) is often
reduced to gold(I) when introduced into a physiological environment (Bertrand, 2018).
Four gold(I) chloride compounds synthesized by the Department of Chemistry and
Biochemistry at DePaul University in the lab of Dr. Kyle Grice were examined for their efficacy
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as potential therapeutic agents by inhibiting cell proliferation and inducing cell death in breast
cancer cells (Table 3). The four compounds vary in size, mass and structure.
Trimethylphosphine gold(I) chloride (PMe3AuCl) is a small and compact compound with
three methyl groups attached to the phosphine center and has a molecular weight of 308.503
g/mol.
Tri-isopropylphosphine gold(I) chloride (PiPr3AuCl) is a larger slightly more branched
compound with three isopropyl groups attached to a phosphine center and has a molecular
weight of 392.663 g/mol.
Tri-tert-butylphosphine gold(I) chloride (PtBu3AuCl) is the third largest compound and is
more branched than PiPr3AuCl with three tert-butyl groups attached to a phosphine center and
has a molecular weight of 434.743 g/mol.
Tricyclohexylphosphine gold(I) chloride (PCy3AuCl) is the largest of the four
compounds with three cyclohexyl groups attached to a phosphine center and has a molecular
weight of 512.853 g/mol.
As stated earlier, gold compounds are thought to have an effect on many different cellular
processes. Therefore, it is hypothesized that these gold(I) compounds will inhibit cell
proliferation and induce cellular apoptosis in MDA-MB-231 triple negative breast cancer cells.

15

Table 3: Gold(I) chloride compound names and structures
Name

Structure

Name

PMe3AuCl

PtBu3AuCl

(MW: 308.50)

(MW: 434.74)

PiPr3AuCl

PCy3AuCl

(MW: 392.66)

(MW: 512.85)

Structure

Gold compounds are a class of metallo-drugs that have long been studied as a possible
treatment for cancers (Nobili, 2009). One well-known gold(I) compound is Auranofin. Presently,
Auranofin is used to treat severe rheumatoid arthritis (Messori, 2004). A 2013 study showed that
Auranofin has antiproliferative effects in MDA-MB-231 breast cancer cells, however the
mechanism of action is uncertain (Kim, 2013).
It is hypothesized that gold compounds are likely involved in direct DNA and
mitochondrial damage resulting in modification of the cell cycle and eventually apoptosis
(Nobili, 2009). The following three characteristics of gold compounds may be of importance
when considering a mechanism of action.
-

Gold compounds, such as Auranofin, can tightly bind to side chains of other
biomolecules such as proteins, enzymes and DNA.

-

Gold compounds are also large cations that can cross membranes and strongly bind to
biomolecules.

-

Gold compounds can also affect redox chemistry resulting in oxidative damage
(Nobili, 2009). Previous studies have shown that gold compounds interact with the
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thioredoxin system. It has also been shown that a cytosolic thioredoxin isoform, Trx1,
is expressed at increased levels in many human carcinomas (Engman, 2006).
Apoptosis is programmed cell death that is generally accompanied by increased
production of reactive oxygen species (ROS) (Nobili, 2009). Recent studies have suggested that
gold compounds can act as an inhibitor of thioredoxin reductase (TrxR), which leads to increased
production of hydrogen peroxide within the cell which eventually leads to apoptosis. Expression
of TrxR counteracts hydrogen peroxide production (Marzano, 2007).
The other conjectures for general modes of action exhibited by gold compounds include
direct DNA damage, cell cycle arrest, topoisomerase inhibition, specific kinase inhibition and
inhibition of other transcriptional factors (Bindoli, 2009, Chaves, 2014, Walther, 2017, Zou,
2016).

Materials and Methods
Cell Line:
MDA-MB-231 breast cancer cell line was obtained from the American Type Culture
Collection (Manassas, Va., USA). The MDA-MB-231 cell line is an epithelial human breast
cancer cell line from a pleural effusion of a 51-year-old Caucasian female with metastatic
mammary adenocarcinoma. MDA-MB-231 is a commonly used breast cancer cell line in
medical research laboratories. It is a highly aggressive and invasive triple negative breast cancer
cell line lacking receptors for ER and PGR and HER2 (ATCC, 2020). Cells were grown as a
monolayer in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), and 1% penicillin/streptomycin. Cells were maintained in 75-cm2 culture
flasks at 37 C with 5% CO2 and 95% humidity. The cells were passaged once a week by routine
trypsinization.

Preparation of Solutions & Reagents:
DMEM powder was purchased from Sigma-Aldrich Chemical Company (St. Louis, MO.
USA) and stored at 4 C. DMEM was prepared by first dissolving the powder in deionized
water, supplementing the solution with sodium bicarbonate, then adjusting the pH of the solution
between 7.20 and 7.40 by addition of HCl. DMEM solution was then filter sterilized using a
filter with a porosity of 0.22 microns, and the final pH was determined to be 7.20. DMEM
17

supplemented with FBS, penicillin/streptomycin and sodium pyruvate buffer will be referred to
as complete, while DMEM not supplemented with FBS and penicillin/streptomycin, and sodium
pyruvate buffer will be referred to as incomplete.
Hank’s Balanced Salt Solution (HBSS) (pH 7.0) was used to wash cells during passaging.
HBSS powder was purchased from Sigma-Aldrich Chemical Company (St. Louis, MO, USA)
and stored at 4 C. HBSS was prepared by first dissolving the powder in diH2O. The solution
was supplemented with sodium bicarbonate and then the pH was adjusted between 7.20 and 7.40
by addition of HCl. HBSS was then filter sterilized and the final pH was calculated to be 7.20.
Acridine orange and propidium iodide used for the apoptosis assay were diluted in deionized water to a concentration of 100 μg/ml.
Triaminopyrimidine compounds, CK-1-41 derivative compounds and gold(I) chloride
compounds were dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich) and were added to
cell cultures at the desired concentrations in culture medium.

Cell Proliferation
The effects of triaminopyrimidine derivatives and gold(I) chloride compounds on cell
proliferation were assessed by using the 3-[4,5-dimethyl-2-thiazolyl]-2,5-diphenyl-2Htetrazolium bromide (MTT) assay. The MTT assay is commonly used to measure cell
proliferation and viability and functions by measuring the reduction of yellow MTT by
mitochondrial dehydrogenases of viable cells to yield purple formazan crystals, which can be
detected at 590 nm. The MTT assay was performed according to the manufacturer’s instructions
(Sigma). Briefly, MDA-MB-231 breast cancer cells were seeded in 24-well plates at
approximately 3 × 105 cells/well. They were allowed to attach overnight and were then nutrient
starved for 24 hours by replacing the medium with incomplete DMEM. The cells were exposed
to various concentrations of triaminopyrimidine derivatives (1 nM, 100 nM, 1 M, 10 M, and
20 M) for 24, 48 and 72 hours or various concentrations of gold(I) chloride compounds (0.1
M, 0.5 M, 1 M, 2.5 M, 5 M, and 7.5 M) for 72 hours. Cells were then incubated for 2
hours in the presence of MTT at 10% of the cell culture volume. After the incubation period, the
resulting formazan crystals were dissolved in MTT solubilization solution (10% Triton X-100,
0.1 HCl in isopropanol). The absorbance of the resulting solution was measured at 570 nm, and
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the background absorbance was measured at 690 nm. The background reading was subtracted
from the A570 measurement, and cell survival was calculated as a percentage of the control.

Apoptosis
Early stages of apoptosis can be detected with an apoptosis assay, which involves
staining and observing cells with fluorescence microscopy. Two stains that can be used to detect
apoptotic cells are propidium iodide and acridine orange. Propidium Iodide was used to observe
the difference between apoptotic and necrotic cells. Necrotic cells are permeable to propidium
iodide whereas apoptotic cells are not. Propidium Iodide will stain the nucleus of necrotic cells
red (Baskić, 2006).
Acridine Orange is a stain that is commonly used in conjunction with an additional stain,
such as Propidium Iodide. Acridine Orange is selective for nucleic acids and interacts with DNA
and RNA by intercalation (Gherghi, 2003). Acridine Orange permeates all cells and stains the
nucleus green, whereas only cells that have lost cytoplasmic membrane integrity take up
propidium iodide and stain red (Gherghi, 2003).
Apoptosis was assayed by examining cytoplasmic condensation and nuclear
fragmentation, two hallmarks of apoptotic cells, using differential uptake of the fluorescent
DNA-binding dyes propidium iodide and acridine orange. Acridine orange permeates all cells
and stains the nucleus green, whereas propidium iodide is taken up by cells with compromised
cell membrane integrity and stains the nucleus red. Healthy cells take up acridine orange but not
propidium iodide and are stained green with a normal nuclear morphology. Early apoptotic cells
also take up acridine orange but are identified by a condensed or fragmented nucleus. Late
apoptotic cells take up both dyes and display a condensed and fragmented orange chromatin.
These are differentiated from necrotic cells, which have a structurally normal but orange nucleus
(Figure 3).
The propidium iodide/acridine orange apoptotic assay was conducted as described with a
few modifications. MDA-MB-231 cells were seeded in T-25 tissue culture flasks and allowed to
attach overnight. They were nutrient starved in DMEM without FBS for 24 hours and then
exposed to treatment for 48 hours. Cells were trypsinized and counted to 1 × 103 per mL of
media. About 10 μL of both acridine orange (100 μg/ml) and propidium iodide (100 μg/ml) was
added to the cell suspension. About 15 μL of cell suspension was placed on a glass microscope
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slide and was examined using a Nikon Eclipse E600 fluorescence microscope at 20x
magnification with a 480/30-nm excitation filter, 505-nm LP dichromatic mirror cut-on, and
535/40-nm barrier filter (Nikon, Melville, NY, USA). Each experiment was carried out in
triplicate. A total of approximately 200 cells in 10 to 15 fields per treatment were counted for
analysis. Cells were categorized by their appearance and the color of dye taken up. Cells stained
a solid green were counted as viable. Cells stained green but appeared to have a fragmented
nucleus or displayed blebbing were counted as early apoptotic. Cells that appeared to have taken
up both dyes were counted as late apoptotic. Cells that stained bright orange or red were counted
as necrotic. Cells categorized as early apoptotic, late apoptotic, and necrotic were collated as
apoptotic. The percentage of apoptosis was calculated as the total number of apoptotic cells
divided by the number of total cells counted multiplied by 100.

Figure 4: A picture from the apoptosis assay indicating the
four different stages of apoptosis. Viable cells are stained
solid green with a clearly defined nucleus. Early apoptotic
cells are stained green with a fragmented nucleus. Late
apoptotic cells are stained both green and orange. Necrotic
cells are stained orange with cell blebbing.

Probit Analysis
For the cell proliferation assay a Probit analysis was conducted in order to determine the
relative toxicity of each compound. Probit analysis was not performed for compounds that did
not affect cell survival. Percent values for cell proliferation were converted to probability units
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using Finney’s table (Finney, 1952). The probability units were then plotted against the log of
the concentrations tested and fit with a regression line to determine the IC50 value for each
compound (Tables 4, 5 and 6). Standard error for the IC50 values was calculated by Linest
analysis. An IC50 value represents the concentration of a compound required for 50% inhibition
of cell proliferation.
Statistical Significance
A Student’s t-test for one-way analysis of variance was used to assess differences
between untreated control groups and groups treated with a triaminopyrimidine compound or a
gold(I) chloride compound. A p-value < 0.05 was considered statistically significant.

Results:
1. The Effect of Triaminopyrimidine Analogs on MDA-MB-231 Cell Proliferation
1.1 CK-1-29: A statistically significant decrease in percent cell survival was observed in
MDA-MB-231 cells treated with compound CK-1-29 (Figure 5) at a concentration of 20 µM for
24 hours (27%), 48 hours (54%), 72 hours (41%). A Probit analysis was conducted and IC50
values (Table 4) were calculated for 24-hour (18.41 M) and 48-hour (27.18 M) incubation
times.

1.2 CK-1-37: No statistically significant decreases in percent cell survival were observed
in MDA-MB-231 cells treated with compound CK-1-37 (Figure 6). A Probit analysis was
conducted and an IC50 value (Table 4) was calculated for a 48-hour incubation time (45.03 M).

1.3 MB-1-19: No statistically significant decreases in percent cell survival were observed
in MDA-MB-231 cells treated with compound MB-1-19 (Figure 7).

1.4 CK-1-41: A statistically significant decrease in percent cell survival was observed in
MDA-MB-231 cells treated with compound CK-1-41 (Figure 8) at concentrations of 10 M for
72 hours (40%) and 20 µM for 24 hours (54%) and 72 hours (65%). A Probit analysis was
conducted and an IC50 value (Table 4) was calculated for a 72-hour incubation time (13.42 M).
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The Effect of CK-1-29 on MDA-MB-231 Cell Proliferation
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Figure 5. The effect of triaminopyrimidine analog compound CK-1-29 on MDA-MB-231 cell proliferation.
MDA-MB-231 cells were treated with concentrations of 1 nM, 100 nM, 1 μM, 10 μM, and 20 μM for 24, 48
and 72 hours. Experiments were replicated in sets of three and cell proliferation was calculated by the MTT
assay. Percent cell survival is given as a percentage of the control. The dashed line denotes the control.

The Effect of CK-1-37 on MDA-MB-231 Cell Proliferation
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Figure 6. The effect of triaminopyrimidine analog compound CK-1-37 on MDA-MB-231 cell proliferation.
MDA-MB-231 cells were treated with concentrations of 1 nM, 100 nM, 1 μM, 10 μM, and 20 μM for 24, 48
and 72 hours. Experiments were replicated in sets of three and cell proliferation was calculated by the MTT
assay. Percent cell survival is given as a percentage of the control. The dashed line denotes the control.
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The Effect of MB-1-19 on MDA-MB-231 Cell Proliferation
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Figure 7. The effect of triaminopyrimidine analog compound MB-1-19 on MDA-MB-231 cell proliferation.
MDA-MB-231 cells were treated with concentrations of 1 nM, 100 nM, 1 μM, 10 μM, and 20 μM for 24, 48
and 72 hours. Experiments were replicated in sets of three and cell proliferation was calculated by the MTT
assay. Percent cell survival is given as a percentage of the control. The dashed line denotes the control.

The Effect of CK-1-41 on MDA-MB-231 Cell Proliferation
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Figure 8. The effect of triaminopyrimidine analog compound CK-1-41 on MDA-MB-231 cell proliferation.
MDA-MB-231 cells were treated with concentrations of 1 nM, 100 nM, 1 μM, 10 μM, and 20 μM for 24, 48
and 72 hours. Experiments were replicated in sets of three and cell proliferation was calculated by the MTT
assay. Percent cell survival is given as a percentage of the control. The dashed line denotes the control.
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Table 4: IC50 Values for Triaminopyrimidine Analog Compounds
Compound

Incubation Time (Hours)

IC50 Value M

48

18.41

72

27.18

CK-1-37

48

45.03

CK-1-41

72

13.42

CK-1-29

2. The Effect of CK-1-41 Derivatives on MDA-MB-231 Cell Proliferation
Based on the cell proliferation results of the triaminopyrimdine analog CK-1-41 the
largest decrease in cell survival was observed at 72 hours. Therefore, CK-1-41 derivatives were
tested at 48- and 72-hour incubation times only.

2.1 AE-2-23: A statistically significant decrease in percent cell survival was observed in
MDA-MB-231 cells treated with compound AE-2-23 (Figure 9) at a concentration of 20 µM for
48 hours (65%). A Probit analysis was conducted and an IC50 value (Table 4) was calculated for
a 72-hour incubation time (4.54 M).

2.2 AE-1-75: A statistically significant decrease in percent cell survival was observed in
MDA-MB-231 cells treated with compound AE-1-75 (Figure 10) at concentrations of 10 M for
72 hours (50%) and 20 M for 48 hours (62%) and 72 hours (63%). A Probit analysis was
conducted and an IC50 value (Table 5) was calculated for a 72-hour incubation time (18.92 M).

2.3 AE-1-63: A statistically significant decrease in percent cell survival was observed in
MDA-MB-231 cells treated with compound AE-1-63 (Figure 11) at concentrations of 1 nM
(29%), 100 nM (42%), 1 M (27%), 10 M (31%) and 20 M (62%) for 48 hours and at
concentrations of 1 nM (31%), 100 nM (34%), 10 M (28%) and 20 M (43%) for 72-hours. A
Probit analysis was conducted and an IC50 value (Table 5) was calculated for a 48-hour
incubation time (20.54 M).
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2.4 AE-1-79: A statistically significantly decrease in percent cell survival was observed
in MDA-MB-231 cells treated with compound AE-1-79 (Figure 12) at concentrations of 10 M
for 72 hours (32%) and 20 M for 48 hours (25%) and 72 hours (36%). A Probit analysis was
conducted and IC50 values (Table 5) were calculated for 48-hour (82.80 M) and 72-hour
(214.70 M) incubation times.
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The Effect of AE-2-23 on MDA-MB-231 Cell Proliferation
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Figure 9. The effects of CK-1-41 derivative compounds AE-2-23 on MDA-MB-231 cell proliferation. MDAMB-231 cells were treated with concentrations of 1 nM, 100 nM, 1 μM, 10 μM, and 20 μM for 48 and 72
hours. Experiments were replicated in sets of three and cell proliferation was calculated by the MTT assay.
Percent cell survival is given as a percentage of the control. The dashed line denotes the control.

The Effect of AE-1-75 on MDA-MB-231 Cell Proliferation
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Figure 10. The effects of CK-1-41 derivative compounds AE-1-75 on MDA-MB-231 cell proliferation.
MDA-MB-231 cells were treated with concentrations of 1 nM, 100 nM, 1 μM, 10 μM, and 20 μM for 48 and
72 hours. Experiments were replicated in sets of three and cell proliferation was calculated by the MTT assay.
Percent cell survival is given as a percentage of the control. The dashed line denotes the control.
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The Effect of AE-1-63 on MDA-MB-231 Cell Proliferation
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Figure 11. The effects of CK-1-41 derivative compounds AE-1-63 on MDA-MB-231 cell proliferation.
MDA-MB-231 cells were treated with concentrations of 1 nM, 100 nM, 1 μM, 10 μM, and 20 μM for 48 and
72 hours. Experiments were replicated in sets of three and cell proliferation was calculated by the MTT assay.
Percent cell survival is given as a percentage of the control. The dashed line denotes the control.

The Effect of AE-1-79 on MDA-MB-231 Cell Proliferation
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Figure 12. The effects of CK-1-41 derivative compounds AE-1-79 on MDA-MB-231 cell proliferation. MDAMB-231 cells were treated with concentrations of 1 nM, 100 nM, 1 μM, 10 μM, and 20 μM for 48 and 72 hours.
Experiments were replicated in sets of three and cell proliferation was calculated by the MTT assay. Percent
cell survival is given as a percentage of the control. The dashed line denotes the control.
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Table 5: IC50 Values for CK-1-41 Derivative Compounds
Compound

Incubation Time (Hours)

IC50 Value M

AE-2-23

72

4.54

AE-1-63

48

20.54

AE-1-75

72

18.92

48

82.80

72

214.70

AE-1-79

3. The Effect of Triaminopyrimidine Analogs on MDA-MB-231 Apoptosis
For most of the triaminopyrimidine analog compounds a statistically significant
difference was not observed between the percentage of early apoptotic cells and necrotic cells
compared to the control . The significant results will be stated for each compound. The apoptosis
micrographs in the figures below contain three different types of pictures. The first picture with
green fluorescing cells depicts MDA-MB-231 cells stained with acridine orange. Green
fluorescence represents viable or early apoptotic cells. The second picture with red fluorescing
cells depicts MDA-MB-231 cells stained with propidium iodide. Red fluorescence represents late
apoptotic or necrotic cells. The third picture contains a merged image of both stains.

3.1 CK-1-29: No statistically significant increase in apoptosis was observed in MDAMB-231 cells treated with compound CK-1-29 (Figures 13 and 14) at a concentration of 20 M
for 48 hours compared to the control.

3.2 CK-1-37: A statistically significant increase in apoptosis (7.5%), early apoptosis
(4.8%), and necrosis (2.7%) was observed in MDA-MB-231 cells treated with compound CK-137 (Figures 15 and 16) at a concentration of 20 M for a period of 48 hours compared to the
control.

3.3 CK-1-41: No statistically significant increase in apoptosis was observed in MDAMB-231 cells treated with compound CK-1-41 (Figures 17 and 18) at a concentration of 20 M
for 48 hours compared to the control.
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Figure 13. MDA-MB-231 cells treated with compound CK-1-29 and stained with Acridine
Orange and Propidium Iodide at a concentration of 1mg/mL for 15 minutes. Experiments were
replicated in sets of three.
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Figure 14. The effects of CK-1-29 compound on MDA-MB-231 cellular apoptosis. Depicted is the
percentage of viable cells compared to apoptotic cells. MDA-MB-231 cells were treated with
compound concentration of 20 μM for 48 hours. Experiments were replicated in sets of three and
control groups were treated with DMSO.
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Figure 15. MDA-MB-231 cells treated with compound CK-1-37 and stained with Acridine
Orange and Propidium Iodide at a concentration of 1mg/mL for 15 minutes. Experiments were
replicated in sets of three.
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Figure 16. The effects of CK-1-37 compound on MDA-MB-231 cellular apoptosis. Depicted is
the percentage of viable cells compared to apoptotic cells. MDA-MB-231 cells were treated with
compound concentration of 20 μM for 48 hours. Experiments were replicated in sets of three and
control groups were treated with DMSO.
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Figure 17. MDA-MB-231 Cells treated with compound CK-1-41 and stained with Acridine
Orange and Propidium Iodide at a concentration of 1mg/mL for 15 minutes. Experiments
were replicated in sets of three.
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Figure 18. The effects of CK-1-41 compound on MDA-MB-231 cellular apoptosis. Depicted is
the percentage of viable cells compared to apoptotic cells. MDA-MB-231 cells were treated with
compound concentration of 20 μM for 48 hours. Experiments were replicated in sets of three and
control groups were treated with DMSO.
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4. The Effect of CK-1-41 Derivatives on MDA-MB-231 Apoptosis
4.1 AE-2-23: No statistically significant increase in apoptosis was observed in MDAMB-231 cells treated with compound AE-2-23 (Figures 19 and 20) at a concentration of 20 M
for 48 hours compared to the control.

4.2 AE-1-75: A statistically significant increase in apoptosis (2.5%) and early apoptosis
(6.2%) was observed in MDA-MB-231 cells treated with compound AE-1-75 (Figure 21 and 22)
at a concentration of 20 M for 48 hours compared to the control.

4.3 AE-1-79: A statistically significant increase in apoptosis (3.1%) and early apoptosis
(6.7%) was observed in MDA-MB-231 cells treated with compound AE-1-79 (Figure 23 and 24)
at a concentration of 20 M for 48 hours compared to the control.

4.4 AE-1-63: No statistically significant increase in apoptosis was observed in MDAMB-231 cells treated with compound AE-1-63 (Figure 25 and 26) at a concentration of 20 M
for 48 hours compared to the control.
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Figures 19. Figures show MDA-MB-231 Cells treated with compound AE-2-23 and stained with
Acridine Orange and Propidium Iodide at a concentration of 1mg/mL for 15 minutes.
Experiments were replicated in sets of three.
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Figure 20. The effects of AE-2-23 compound on MDA-MB-231 cellular apoptosis. Depicted is
the percentage of viable cells compared to apoptotic cells. MDA-MB-231 cells were treated with
compound concentration of 20 μM for 48 hours. Experiments were replicated in sets of three and
control groups were treated with DMSO.
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Figure 21. MDA-MB-231 cells treated with compound AE-1-75 and stained with Acridine Orange
and Propidium Iodide at a concentration of 1mg/mL for 15 minutes. Experiments were replicated
in sets of three.
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Figure 22. The effects of AE-1-75 compound on MDA-MB-231 cellular apoptosis. Depicted is
the percentage of viable cells compared to apoptotic cells. MDA-MB-231 cells were treated with
compound concentration of 20 μM for 48 hours. Experiments were replicated in sets of three and
control groups were treated with DMSO.
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Figure 23. MDA-MB-231 cells treated with compound AE-1-79 and stained with Acridine Orange
and Propidium Iodide at a concentration of 1mg/mL for 15 minutes. Experiments were replicated
in sets of three.
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Figure 24. The effects of AE-1-79 compound on MDA-MB-231 cellular apoptosis. Depicted is
the percentage of viable cells compared to apoptotic cells. MDA-MB-231 cells were treated with
compound concentration of 20 μM for 48 hours. Experiments were replicated in sets of three and
control groups were treated with DMSO.

35

PI

Merged

AE-1-63 20µM

Control

AO

Figure 25. Figures show MDA-MB-231 Cells treated with compound AE-1-63 and stained with
Acridine Orange and Propidium Iodide at a concentration of 1mg/mL for 15 minutes.
Experiments were replicated in sets of three.
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Figure 26. The effects of AE-1-63 compound on MDA-MB-231 cellular apoptosis. Depicted is
the percentage of viable cells compared to apoptotic cells. MDA-MB-231 cells were treated with
compound concentration of 20 μM for 48 hours. Experiments were replicated in sets of three and
control groups were treated with DMSO.
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5. The Effect of Gold(I) Chloride Compounds on MDA-MB-231 Cell Proliferation
5.1 Trimethylphopshine gold(I) chloride: A statistically significant decrease in percent
cell survival was observed in MDA-MB-231 cells treated with compound PMe3AuCl (Figure 27)
at concentrations of 0.1 M (24%), 0.5 M (68%), 1 M (90%), 2.5 M (96%), 5 M (97%),
and 7.5 M (97%) for 72 hours. A Probit analysis was conducted (Figure 28) and an IC50 value
(Table 6) was observed for a 72-hour incubation time (0.10 ± 0.39 M).

5.2 Tricyclohexylphosphine gold(I) chloride: A statistically significant decrease in
percent cell survival was observed in MDA-MB-231 cells treated with compound PCy3AuCl
(Figure 29) at concentrations of 2.5 M (89%), 5 M (96%), and 7.5 M (96%) for 72 hours. A
Probit analysis was conducted (Figure 30) and an IC50 value (Table 6) was observed for a 72hour incubation time (1.70 ± 0.96 M).

5.3 Tri-tert-butylphosphine gold(I) chloride: A statistically significant decrease in
percent cell survival was observed in MDA-MB-231 cells treated with compound PtBu3AuCl
(Figure 31) at concentrations of 0.5 M (29%), 1 M (37%), 2.5 M (92%), 5 M (98%), and
7.5 M (98%) for 72 hours. A Probit analysis was conducted (Figure 32) and an IC50 value
(Table 6) was observed for a 72-hour incubation time (0.93 ± 0.40 M).

5.4 Tri-isopropylphosphine gold(I) chloride: A statistically significant decrease in
percent cell survival was observed in MDA-MB-231 cells treated with compound PiPr3AuCl
(Figure 33) at concentrations of 2.5 M (60%), 5 M (97%), and 7.5 M (97%). A Probit
analysis was conducted (Figure 34) and an IC50 value (Table 6) was observed for a 72-hour
incubation time (1.50 ± 0.96 M).
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The Effect of Trimethylphospine gold(I) chloride on MDA-MB-231 Cell Proliferation
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Figure 27. The effects of gold(I) chloride compound PMe3AuCl on MDA-MB-231 cell proliferation.
MDA-MB-231 cells were treated with concentrations of 0.1 μM, 0.5 μM, 1 μM, 2.5 μM, 5 μM, and 7.5 μM
for 72 hours. Experiments were replicated in sets of three and cell proliferation was calculated by the MTT
assay. Percent cell survival is given as a percentage of the control. The dashed line denotes the control.
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Figure 28. Probit analysis of MDA-MB-231 cell proliferation dose response to compound PMe 3AuCl.
MDA-MB-231 cells were treated with compound concentrations of 0.1 μM, 0.5 μM, 1 μM, 2.5 μM, 5
μM, and 7.5 μM. Experiments were replicated in sets of three and Probit values were determined by
converting percent mortality to probability units using Finney’s Table.
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The Effect of Tricyclohexylphosphine gold(I) chloride on MDA-MB-231
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Figure 29. The effects of gold(I) chloride compound PCy3AuCl on MDA-MB-231 cell proliferation. MDAMB-231 cells were treated with concentrations of 0.1 μM, 0.5 μM, 1 μM, 2.5 μM, 5 μM, and 7.5 μM for 72
hours. Experiments were replicated in sets of three and cell proliferation was calculated by the MTT assay.
Percent cell survival is given as a percentage of the control. The dashed line denotes the control.
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Figure 30. Probit analysis of MDA-MB-231 cell proliferation dose response to compound PCy 3AuCl. MDAMB-231 cells were treated with compound concentrations of 0.1 μM, 0.5 μM, 1 μM, 2.5 μM, 5 μM, and
7.5 μM. Experiments were replicated in sets of three and Probit values were determined by converting percent
mortality to probability units using Finney’s Table.
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Figure 31. The effects of gold(I) chloride compound PtBu3AuCl on MDA-MB-231 cell proliferation. MDAMB-231 cells were treated with concentrations of 0.1 μM, 0.5 μM, 1 μM, 2.5 μM, 5 μM, and 7.5 μM for 72
hours. Experiments were replicated in sets of three and cell proliferation was calculated by the MTT assay.
Percent cell survival is given as a percentage of the control. The dashed line denotes the control.
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Figure 32. Probit analysis of MDA-MB-231 cell proliferation dose response to compound PtBu3AuCl. MDAMB-231 cells were treated with compound concentrations of 0.1 μM, 0.5 μM, 1 μM, 2.5 μM, 5 μM, and
7.5 μM. Experiments were replicated in sets of three and Probit values were determined by converting percent
mortality to probability units using Finney’s Table.
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The Effect of Tri-isopropylphosphine gold(I) chloride on MDA-MB-231
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Figure 33. The effects of gold(I) chloride compound PiPr3AuCl on MDA-MB-231 cell proliferation. MDAMB-231 cells were treated with concentrations of 0.1 μM, 0.5 μM, 1 μM, 2.5 μM, 5 μM, and 7.5 μM for 72
hours. Experiments were replicated in sets of three and cell proliferation was calculated by the MTT assay.
Percent cell survival is given as a percentage of the control. The dashed line denotes the control.
The Effect of Tri-isopropylphosphine gold(I) chloride on MDA-MB-231
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Figure 34. Probit analysis of MDA-MB-231 cell proliferation dose response to compound PiPr3AuCl. MDAMB-231 cells were treated with compound concentrations of 0.1 μM, 0.5 μM, 1 μM, 2.5 μM, 5 μM, and
7.5 μM. Experiments were replicated in sets of three and Probit values were determined by converting percent
mortality to probability units using Finney’s Table.

41

Table 6: IC50 Values for Gold(I) Chloride Compounds
Compound

Incubation Time (Hours)

1.50 ± 0.96

PiPr3AuCl
PtBu3AuCl
PCy3AuCl

IC50 Value M

72

0.93 ± 0.40
1.70 ± 0.96
0.10 ± 0.39

PMe3AuCl

6. The Effect of Gold(I) Chloride Compounds on MDA-MB-231 Apoptosis
6.1 Trimethylphopshine gold(I) chloride: A statistically significant increase in apoptosis
(52.5%) and early apoptosis (28.6%) was observed in MDA-MB-231 cells treated with
compound PMe3AuCl (Figures 35 and 36) at a concentration of 0.5 M for 48 hours.

6.2 Tricyclohexylphosphine gold(I) chloride: No statistically significant increase in
apoptosis was observed in MDA-MB-231 cells treated with PCy3AuCl (Figures 37 and 38) at a
concentration of 2.5 M for 48 hours.

6.3 Tri-tert-butylphosphine gold(I) chloride: A statistically significant increase in
apoptosis (19.4%) was observed in MDA-MB-231 cells treated with compound PtBu3AuCl
(Figures 39 and 40) at a concentration of 0.5 M for 48 hours.

6.4 Tri-isopropylphosphine gold(I) chloride: No statistically significant increase in
apoptosis was observed in MDA-MB-231 cells treated with PiPr3AuCl (Figures 41 and 42) at a
concentration of 2.5 M for 48 hours.
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Figure 35. MDA-MB-231 cells treated with compound PMe3AuCl and stained with Acridine
Orange and Propidium Iodide at a concentration of 1mg/mL for 15 minutes. Experiments were
replicated in sets of three.
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Figure 36. The effects of PMe3AuCl compound on MDA-MB-231 cellular apoptosis. Depicted is the
percentage of viable cells compared to apoptotic cells. MDA-MB-231 cells were treated with
compound concentration of 0.5 μM for 48 hours. Experiments were replicated in sets of three and
control groups are treated with DMSO.
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Figure 37. MDA-MB-231 cells treated with compound PCy3AuCl and stained with Acridine
Orange and Propidium Iodide at a concentration of 1mg/mL for 15 minutes. Experiments were
replicated in sets of three.
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Figure 38. The effects of PCy3AuCl compound on MDA-MB-231 cellular apoptosis. Depicted is the
percentage of viable cells compared to apoptotic cells. MDA-MB-231 cells were treated with
compound concentration of 2.5 μM for 48 hours. Experiments were replicated in sets of three and
control groups are treated with DMSO.
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Figure 39. MDA-MB-231 cells treated with compound PtBu3AuCl and stained with Acridine
Orange and Propidium Iodide at a concentration of 1mg/mL for 15 minutes. Experiments were
replicated in sets of three.
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Figure 40. The effects of PtBu3AuCl compound on MDA-MB-231 cellular apoptosis. Depicted is
the percentage of viable cells compared to apoptotic cells. MDA-MB-231 cells were treated with
compound concentration of 0.5 μM for 48 hours. Experiments were replicated in sets of three and
control groups are treated with DMSO.
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Figure 41. MDA-MB-231 cells treated with compound PiPr3AuCl and stained with Acridine
Orange and Propidium Iodide at a concentration of 1mg/mL for 15 minutes. Experiments were
replicated in sets of three.
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160
Control

Percentage of Total

140

PiPr₃AuCl

120
100
80
60
40
20
0
Viable

Apoptotic

Early Apototic

Necrotic

Cell Stage

Figure 42. The effects of PiPr3AuCl compound on MDA-MB-231 cellular apoptosis. Depicted is
the percentage of viable cells compared to apoptotic cells. MDA-MB-231 cells were treated with
compound concentration of 2.5 μM for 48 hours. Experiments were replicated in sets of three and
control groups are treated with DMSO.
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Discussion
The purpose of this study was to quantify the effects of triaminopyrimidine analogs and
gold(I) compounds on cell proliferation and apoptosis in MDA-MB-231 human breast cancer
cells that are known to be negative for ER, PR and HER2. By identifying these effects, we can
ascertain in a preliminary manner the efficacy of these new compounds in breast cancer
chemotherapy. By using the human triple negative breast cancer cell line, MDA-MB-231, as a
model, it was possible to test for a decrease in cell viability and an increase in apoptosis, that
perhaps might shed light on their therapeutic potential in the cohort of patients with a triple
negative breast cancer diagnosis for which there is very little by way of existing targeted therapy.
The triaminopyrimidine analogs were previously found to inhibit inflammasome
formation of caspase 1, 4 and 5 in a noncompetitive and time dependent manner (Kent, 2016).
Caspases are a family of cysteine proteases that play a critical role in cellular apoptosis and
proteolytic activation of cytokines (Boatright, 2003). Pro-inflammatory cytokines are detected at
high levels in cancer patients and are suggested to promote an immune-suppressive tumor
microenvironment (Zitvogel, 2012). It has previously been reported that chronic inflammation is
associated with an unfavorable clinical prognosis of cancer patients (Grivennikov, 2010 &
Baniyash, 2014).
CK-1-41 is the triaminopyrimidine compound that resulted in the largest and most
significant decrease in percent cell viability. A possible explanation for the success of CK-1-41
could be that it may inhibit the activation of caspase-1 therefore preventing the formation of an
inflammasome (Jin, 2018). The inflammasome is an important innate immune pathway
responsible for the production of mature IL-1β (Jin, 2018). Receptors on the inflammasome can
activate the cysteine protease, caspase-1 (Figure 50) which in turn cleaves the precursor proinflammatory cytokines, pro-IL‐1β and pro-IL-18, into their mature secreted forms (Lamkanfi,
2011). IL-1β is abundant in tumor tissue and increases tumor growth, invasion, carcinogenesis
and host-tumor interactions suggesting that IL-1β is one of the essential components that mediate
inflammation-associated tumor progression (Jin, 2018). A compound that inhibits the formation
of the inflammasome may be a viable treatment option for human breast cancers, therefore it can
be hypothesized that compound CK-1-41 could possibly inhibit cancer cell invasion and cell
proliferation through the inflammatory pathway. As depicted in figure below, moving from the
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bottom to the top, activation of the inflammasome leads to increased levels of caspase 1 within
the cytoplasm. Increased levels of caspase 1 leads to the activation of IL-1β.
Active IL-1β in the cytoplasm leads to increased levels of IL-1β to be released into the
extracellular matrix. Increased levels of IL-1β in the extracellular matrix can cause increased
tumor growth as well as the activation of matrix metalloproteinases (MMPs). The activation of
MMPs leads to an increase in tumor invasion.

Figure 43. A hypothesized mechanism of action for triaminopyrimidine compound CK-1-41 on MDAMB-231 cancer cell line via inflammasome activation. (a) Activation of the inflammasome leads to
increased levels of caspase 1 in cytoplasm allowing pro-IL-1𝛽 to become active IL-1𝛽. Elevated levels of
IL-1𝛽 in the extracellular matrix leads to increased tumor growth. IL-1𝛽 activates MMP leading to
increased tumor invasion. (b) Treatment with CK-1-41 inhibits caspase 1 (Kent 2006 et al) resulting in
inhibition of cleavage of pro- IL-1𝛽 to form the active IL-1𝛽. This inhibition could lead to a decrease in
tumor growth and/or invasion. Figure adapted from Jin et al., 2018.

The inhibition of caspase-1 by compound CK-1-41 may also prevent the activation of
NF-κB. As stated previously, NF-κB promotes tumor cell proliferation, suppresses apoptosis,
and attracts angiogenesis in human cancers (Xia, 2014).
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It can be hypothesized that the presence of triaminopyrimidine compound CK-1-41 in the
cytoplasm lowers the level of caspase-1 therefore preventing the activation of IL-1β. Preventing
the activation of IL-1β would result in lower levels of IL-1β in the extracellular matrix and in
turn, decreased levels of tumor growth and tumor invasion.
A family of zinc-dependent endopeptidases called matrix metalloproteinases (MMPs)
carry out important functions in inflammation and are capable of degrading essentially all
components of the extracellular matrix (Reunanen, 2000 and Parks, 2004). MMPs are
produced by tumor cells and act as regulators of the tumor microenvironment by degrading
basement membranes and stimulating cellular invasion and proliferation. A specific MMP called
matrix metalloproteinase 9 (MMP9) is strongly associated with aggressive and metastatic breast
cancers and the expression of MMP9 is recognized as a poor prognosis signature for breast
cancer patients (van ‘t Veer, 2002). A recent study has discovered that MMP9 is a protease that
cleaves pro-IL-1β and allows for the release of IL-1β from cytokine-activated eosinophils
(Esnault, 2019).
The compound AE-1-75 is the CK-1-41 derivative that resulted in the largest and most
significant decrease in percent cell viability. This compound also had significantly more cells in
the early apoptotic stage when compared to the control. A possible explanation for the
successfulness of compound AE-1-75 is that it is structurally the most similar to compound CK1-41. The only structural difference between the two compounds is the addition of a methyl
group in compound AE-1-75. Both CK-1-41 and AE-1-75 are nonpolar and hydrophobic. As
previously stated, Kent, et al (2016), hypothesizes that the successfulness of compound CK-1-41
may be due to greater structural flexibility. This may be the same reason for the successfulness
of compound AE-1-75, since the two structures are so similar. Structural flexibility seems a more
likely hypothesis than polarity and/or hydrophobicity because other compounds in this study are
nonpolar and hydrophobic but were not successful at inhibiting cellular proliferation.
Gold(I) compounds are known for their inhibition activity towards enzymes involved in
DNA replication and in some cases can inhibit the proliferation of cancer cells by targeting the
mitochondria (Yeo, 2018). Chemical or structural changes within the mitochondria, such as
increased membrane permeability, can lead to autophagy and apoptosis (Si, 2016). PMe3AuCl is
the gold(I) compound that resulted in the largest and most significant decrease in percent cell
viability. The successfulness of PMe3AuCl may be a result of the small size and molecular
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weight of the compound allowing it to cross the membrane and cause DNA damage or
protein/enzyme inhibition, eventually leading to apoptosis. Gold(I) compounds PiPr3AuCl,
PtBu3AuCl and PCy3AuCl also showed significant results in their ability to inhibit MDA-MB231 cell proliferation, however the IC50 values were slightly higher than that of compound
PMe3AuCl. The IC50 values of PiPr3AuCl, PtBu3AuCl and PCy3AuCl were 1.96 M, 0.93 M
and 1.70 M, respectively. It could be suggested that the increased IC50 values are correlated
with the increased bulkiness of the gold(I) compounds. It is important to note that the MTT assay
varies about 20% between replicated experiments and although a statistically significant decrease
in cell survival was not observed for all compounds tested, some effects may still be considered
biologically significant.
It can be proposed that the gold(I) chloride compounds may induce apoptosis by targeting
the mitochondria of the cell, however, further experimentation is required to fully understand this
mechanism. As previously stated, apoptosis is generally accompanied by increased production
of reactive oxygen species (ROS) and recent studies have suggested that gold compounds may
act as an inhibitor of thioredoxin reductase (TrxR), a group of enzymes that reduce the level of a
small protein involved in the regulation of the cellular redox environment called thioredoxin.
Inhibition of TrxR leads to increased production of hydrogen peroxide within the cell which
eventually leads to apoptosis.
It is hypothesized that the gold(I) chloride compounds are able to permeate the
mitochondrial membrane and may interact with mitochondrial thiols that regulate levels of
hydrogen peroxide and influence the cell death pathway. A possible mechanism of action for the
gold(I) chloride compounds could involve inhibition or upregulation of mitochondrial thiols,
creating an imbalance in the cellular redox environment.

Limitations
This is a preliminary study examining the effects of triaminopyrimidine and gold(I)
chloride compounds on the cell proliferation and apoptosis of MDA-MB-231 breast cancer cells.
This study was carried out as a partial fulfillment of a Master’s degree. Further studies need to be
carried out to determine the efficacy of the compounds conclusively. After testing the effects of
the triaminopyrimidine compounds on the MDA-MB-231 triple negative breast cancer cell line
at incubation times of 24, 48, and 72 hours, it was determined that the compounds overall had a
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very minimal effect at 24 hours. Due to this knowledge, the CK-1-41 derivative compounds were
tested for their effects on the MDA-MB-231 cell line at incubation times of 48 and 72 hours
only.
The most significant effects of the triaminopyrimidine derivative compounds and CK-141 analog compounds on MDA-MB-231 cellular proliferation and apoptosis were seen at a 72hour incubation time; because of this the gold(I) chloride compounds used in the second part of
this study were tested for their effects on MDA-MB-231 cellular proliferation and apoptosis at a
72-hour incubation time only. Therefore, the effects of the gold(I) chloride compounds on MDAMB-231 cellular proliferation and apoptosis at 24- and 48-hour incubation times remains
unknown.
Another limitation of this study is that only the in vitro effects of these compounds were
studied for their effects on cell proliferation and apoptosis. Whether these effects, dosages and
times of exposure would translate to the in vivo condition is not known at present. A study out of
the Department of Pharmacology and Experimental Therapeutics at Louisiana State University
and The Stanley S. Scott Cancer Center treated mice with the aromatic hydrocarbon
ethylbenzene to modulate cytochrome P450 enzymes. It was shown that consistent exposure with
ethylbenzene resulted in increased levels of cytochrome P450 (Bergeron, 1999). Cytochrome
P450 enzymes play a role in oxidative metabolism of a wide variety of compounds including
environmental carcinogens and some anticancer drugs (McFadyen, 2004).
As stated previously, this is a preliminary study, not a translational study. This is the first
study to test the effects of these compounds on the cellular proliferation and apoptosis of triple
negative breast cancer cells, hence the effects of these compounds in other cell lines, be they
cancerous or normal cell lines, are unknown.

Future studies
Future experiments will need to be done to determine the mechanism of cytotoxicity of
each compound on healthy and breast cancer cells. In addition to completing the deficiencies
mentioned in the limitation section more experiments will need to be done to explore the specific
molecules (IL – 1, MMPs, thioredoxin reductase, etc.) that could play a role in the possible
mechanisms of compound CK-1-41, particularly its effect on caspase-1 activation.
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Further experiments could be done in order to detect apoptosis. The expression of
phosphatidylserine at the cell surface plays an important role in the recognition and removal of
apoptotic cells by macrophages (Koopman, 1994). Detection of apoptosis by flow cytometry
could be used by adding fluorescein isothiocyanate-labeled annexin V to the breast cancer cells.
The fluorescein isothiocyanate-labeled annexin V will then bind to phosphatidylserine.
The use of fluorochrome-labeled inhibitors of caspases (FLICA) allows for a convenient
estimation of apoptosis by both cytometry and fluorescence microscopy (Pozarowski, 2003).
FLICAs were designed as affinity ligands to active centers of individual caspases. Using the
FLICAs method allows for the detection of caspase activation as well as the different stages of
apoptosis (Pozarowski, 2003).

Conclusion
Of the triaminopyrimidine derivative compounds, CK-1-41 was the most successful at
inhibiting cell proliferation and inducing apoptosis in MDA-MB-231 triple negative breast
cancer cells. Of the CK-1-41 analog compounds, AE-1-75 was the most successful at inhibiting
cell proliferation after a 72-hour incubation time. Of the gold(I) chloride compounds, PMe3AuCl
was the most successful at inhibiting cell proliferation and inducing apoptosis in MDA-MB-231
cells. The triaminopyrimidine derivative compound CK-1-41, the CK-1-41 analog compounds
AE-1-63, AE-1-75, AE-1-79, and AE-2-23, and all four gold(I) chloride compounds, should be
further researched as potential treatment options for triple negative breast cancer.
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